Cargando…

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis

BACKGROUND: In this meta-analysis, we aimed to systematically compare the post percutaneous coronary interventional (PCI) adverse bleeding events, stent thrombosis, stroke and other cardiovascular outcomes in a population of patients with and without thrombocytopenia at baseline who were followed up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Manyun, Ye, Ziliang, Zheng, Jing, Chen, Wuxian, Li, Lang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183593/ https://www.ncbi.nlm.nih.gov/pubmed/32334636 http://dx.doi.org/10.1186/s40360-020-00409-2

Ejemplares similares

Baseline Serum Uric Acid Levels Are Associated with All-Cause Mortality in Acute Coronary Syndrome Patients after Percutaneous Coronary Intervention
por: Ye, Ziliang, et al.
Publicado: (2018)

Efficacy and safety of nicorandil on perioperative myocardial injury in patients undergoing elective percutaneous coronary intervention: results of the PENMIPCI trial
por: Ye, Ziliang, et al.
Publicado: (2018)

Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention
por: Liu, Ru, et al.
Publicado: (2022)

Contrast-induced thrombocytopenia following percutaneous coronary intervention
por: Ferreira, Roberto Muniz, et al.
Publicado: (2017)

Effects of Baseline Thrombocytopenia on In-hospital Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Shiraishi, Jun, et al.
Publicado: (2019)

Association between baseline platelet count and severe adverse outcomes following percutaneous coronary intervention
por: Cheng, Wan–Jun, et al.
Publicado: (2018)

Preoperative Cessation of Both Dual Anti-Platelet Agents Is Safe after 1 Year in Patients Receiving Percutaneous Coronary Intervention
por: Lee, Jeen Hwa, et al.
Publicado: (2020)

Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention
por: Chen, Zhongxiu, et al.
Publicado: (2021)

Reduced Left Ventricular Ejection Fraction Is a Risk Factor for In-Hospital Mortality in Patients after Percutaneous Coronary Intervention: A Hospital-Based Survey
por: Ye, Ziliang, et al.
Publicado: (2018)

The effect of alprostadil on preventing contrast-induced nephropathy for percutaneous coronary intervention in diabetic patients: A systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2016)

Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis
por: Ye, Ziliang, et al.
Publicado: (2017)

Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis
por: Dai, Weiran, et al.
Publicado: (2018)

Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2016)

Long-Term Safety and Efficacy of Prolonged Dual Antiplatelet Therapy according to Baseline Anemia after Percutaneous Coronary Intervention
por: Kim, Hun-Tae, et al.
Publicado: (2022)

Impact of percutaneous coronary intervention on patients with impaired baseline renal function
por: Yadav, Deepti, et al.
Publicado: (2020)

Long-term impact of baseline anaemia on clinical outcomes following percutaneous coronary intervention in stable angina
por: Davidsen, Line, et al.
Publicado: (2020)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Tirofiban: A Rare Cause of Thrombocytopenia in a Patient Undergoing Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report
por: Wang, Ze-Mu, et al.
Publicado: (2023)

Coronary thrombosis due to heparin‐induced thrombocytopenia after percutaneous coronary intervention: Easy to miss, uneasy to prevent
por: Mele, Marco, et al.
Publicado: (2020)

It Is Not Mandatory to Use Triple Rather Than Dual Anti-Platelet Therapy After a Percutaneous Coronary Intervention With a Second-Generation Drug-Eluting Stent
por: Kim, Ju-Youn, et al.
Publicado: (2015)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review
por: Han, Ya-Ling
Publicado: (2019)

Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention
por: Wang, Litao, et al.
Publicado: (2021)

Elevated Baseline Serum Fibrinogen: Effect on 2‐Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention
por: Ang, Lawrence, et al.
Publicado: (2017)

High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention
por: Zhang, Jun-Jie, et al.
Publicado: (2016)

Predictive Value of Fibrinogen-to-Albumin Ratio for Post-Contrast Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention
por: Wang, Can, et al.
Publicado: (2020)

Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
por: Berteotti, M., et al.
Publicado: (2023)

4061 Clinical utility of precision medicine approaches to guide anti-platelet selection for adult patients with acute coronary syndromes (ACS), following percutaneous coronary intervention (PCI)
por: Mosley, Scott, et al.
Publicado: (2020)

An optimal window of platelet reactivity by LTA assay for patients undergoing percutaneous coronary intervention
por: Wang, Jing, et al.
Publicado: (2021)

Percutaneous coronary intervention following Fontan procedure
por: Subahi, Ahmed, et al.
Publicado: (2020)

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Zhou, Yijiang, et al.
Publicado: (2017)

A case report of acute myocardial infarction with extremely severe thrombocytopenia after percutaneous coronary intervention
por: Chen, Shuai, et al.
Publicado: (2023)

Increased platelet reactivity in dyslipidemic patients with coronary artery disease on dual anti-platelet therapy
por: Jäger, Bernhard, et al.
Publicado: (2018)

P2Y(12) Platelet Receptors: Importance in Percutaneous Coronary Intervention
por: Falcão, Felipe Jose de Andrade, et al.
Publicado: (2013)

Platelet Reactivity Was Not Associated with Infarct Size after Primary Percutaneous Coronary Intervention
por: Park, Seohwa, et al.
Publicado: (2021)

Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention
por: Lianos, Ioannis, et al.
Publicado: (2022)

High On-Treatment Platelet Reactivity in Patients Undergoing Complex Percutaneous Coronary Interventions
por: Urban, Lukáš, et al.
Publicado: (2023)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uhqforrp5sake9bqnmtm6ingja